Wei Xiao-Chen, Zhao Ming-Feng, Xiao Xia
Department of Pharmacy, Tianjin First Central Hospital, Tianjin, PR China.
Department of Hematology, Tianjin First Central Hospital, Tianjin, PR China.
J Chemother. 2023 Dec;35(8):721-729. doi: 10.1080/1120009X.2023.2212986. Epub 2023 May 15.
The objective of this study was to evaluate the efficacy of various micafungin dosing regimens against spp. in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT). Monte Carlo simulations were conducted using pharmacokinetic (PK) parameters and pharmacodynamic (PD) data to determine the probabilities of target attainment and cumulative fractions of response in terms of area under the concentration curve/minimum inhibition concentration targets of micafungin. Current standard clinical micafungin dosing regimens of 1 and 2 mg/kg/day were appropriate for the prevention and treatment of infection in pediatric patients undergoing HSCT, respectively. Moreover, the high-dose prophylactic dosage (2 mg/kg/day) and therapeutic dosage (4 mg/kg/day) should be the preferred option to optimize efficacy against . However, none of the simulated regimens was effective against in pediatric HSCT patients. These PK/PD-based simulations rationalize and optimize the micafungin dosing regimens against spp. in pediatric patients undergoing HSCT.
本研究的目的是评估不同米卡芬净给药方案对接受造血干细胞移植（HSCT）的儿科患者中 菌属的疗效。利用药代动力学（PK）参数和药效学（PD）数据进行蒙特卡洛模拟，以根据米卡芬净的浓度曲线下面积/最低抑菌浓度目标确定达到靶标的概率和累积反应分数。当前标准的临床米卡芬净给药方案，即1mg/kg/天和2mg/kg/天，分别适用于接受HSCT的儿科患者预防和治疗 感染。此外，高剂量预防剂量（2mg/kg/天）和治疗剂量（4mg/kg/天）应是优化针对 的疗效的首选方案。然而，模拟的方案中没有一个对儿科HSCT患者中的 有效。这些基于PK/PD的模拟使针对接受HSCT的儿科患者中 菌属的米卡芬净给药方案合理化并进行了优化。
